
|Videos|February 11, 2022
Dr. Dason on selecting neoadjuvant or adjuvant therapy for patients with UTUC
Author(s)Urology Times staff
“We definitely don't have a clear standard,” says Shawn Dason, MD, FRCSC.
Advertisement
In this video, Shawn Dason, MD, FRCSC, discusses the factors that urologists should consider when counseling patients with upper tract urothelial carcinoma about neoadjuvant and adjuvant treatment options. These insights stem from a study that was presented at the 2022 Society of Women in Urology Annual Clinical Mentoring Conference. Dason is a urologic oncologist and an assistant professor of urology at The Ohio State University in Columbus.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
2
FDA approves sildenafil oral film for men with erectile dysfunction
3
Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC
4
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
5






